SecBot SecBot
8-K ·Filed Nov 5, 2026

TFX

TELEFLEX INC
BULLISH
Impact 6/10
Horizonweeks Processed11d 14h ago SEC0000096943-26-000107
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The 39% adjusted EPS beat and raised guidance reflect strong margin execution and aggressive share repurchases. Watch for closing of the Acute Care/Interventional Urology divestiture by year-end, which would fund the remaining $400M buyback authorization and further reduce share count. The EZPLAZ revenue ramp and Freesolve BIOMAG-II data in late 2027 are longer-term catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$152.15
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.66%
T+5 · $153.15
Vs SPY
−2.63%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $152.15entry
  2. T+1 · 11d ago −0.84%α −1.15% · $150.87
  3. T+5 · 5d ago +0.66%α −2.63% · $153.15
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teleflex Q3 2026 revenue of $567.8M was essentially flat YoY (+0.2% reported, +3.0% pro forma adjusted constant currency), while adjusted EPS rose 39% to $2.63, well above the $1.89 consensus. The company raised its full-year adjusted EPS guidance to $7.50-$7.75 from $6.90-$7.20 and maintained its 3.5%-4.5% pro forma revenue growth outlook, citing margin expansion and $350M in share repurchases since July.

Key Financial Metrics

EPS (Adj.)
$2.63
est $1.89 · +39.1% · GAAP: $1.30
Revenue
$567.8M
est $565.4M · +0.4% · +0.2% YoY
Rating
beat
Guidance
$2,256M-$2,276M
raised
Gross Margin
65%

Key Facts

  • Q3 2026 revenue from continuing operations $567.8M, up 0.2% YoY reported, up 3.0% pro forma adjusted constant currency
  • GAAP diluted EPS from continuing operations $1.30 vs $(1.32) in prior year period
  • Adjusted diluted EPS from continuing operations $2.63 vs $1.89 in prior year period, a 39.2% increase
  • Adjusted gross margin 66.8% vs 62.3% in prior year; adjusted operating margin 25.0% vs 22.0%
  • Full year 2026 adjusted EPS guidance raised to $7.50-$7.75 from $6.90-$7.20
  • Pro forma adjusted constant currency revenue growth guidance maintained at 3.5%-4.5%
  • Repurchased $350M of common stock since July 1, 2026 through ASR and open-market purchases
  • Completed OEM divestiture for $1.5B in cash ($1.25B after-tax) on August 3, 2026
  • Received $39.2M in IEEPA tariff refunds during Q3, with $25.3M benefit in continuing operations
  • EZPLAZ freeze-dried plasma received FDA BLA approval; potential long-term U.S. market opportunity of at least $200M
  • Freesolve resorbable magnesium scaffold received FDA Breakthrough Device Designation for PCI

Financial Impact

Adjusted EPS of $2.63 beat consensus of $1.89 by 39.2%; full-year adjusted EPS guidance raised by $0.60 at midpoint to $7.50-$7.75

revenueepsmarginsdilution

Segment Breakdown

SegmentRevenueGrowth
Vascular$243.5M+4.7%
Interventional$210.3M-2.6%
Surgical$114.0M+4.2%

Risk Factors

  • Acute Care/Interventional Urology divestiture closing may extend into 2027, delaying planned capital returns
  • Interventional segment integration remains a work in progress; Q3 pro forma constant currency growth was only 0.2%
  • Adjusted operating margin guidance of ~20% includes $16.5M of IEEPA tariff refunds that may not recur
  • Activist investor campaign noted in legal fees; ongoing pressure could force strategic changes
  • GAAP revenue growth guidance reduced to 13.2%-14.2% due to FX headwinds

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
50% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000096943-26-000107
Exhibit: ex992to11-5x2026req32026.htm0000096943-26-000107
Document: tfx-20261105.htm0000096943-26-000107
Document: 0000096943-26-000107-index-headers.html0000096943-26-000107
Document: 0000096943-26-000107-index.html0000096943-26-000107
Document: 0000096943-26-000107.txt0000096943-26-000107
8-K Data (Synthetic)0000096943-26-000107

Track record

11 reports on TFX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $154.69 Now $157.10 +1.56% settles Nov 23
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $152.15 to $153.15 Now $157.10 +3.25% ▲ +0.66% −2.63% vs SPY
  3. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $138.89 to $137.37 Now $157.10 +13.11% ▼ −1.09% −2.31% vs SPY
  4. Jul 2, 202619w ago Court Ruling Bullish 6/10 Entry $133.99 to $134.04 Now $157.10 +17.25% ▲ +0.04% −0.89% vs SPY
  5. Jun 22, 202621w ago Institutional Cluster Mixed 4/10 Entry $121.67 to $129.86 Now $157.10 +29.12% ▲ +6.73% +8.80% vs SPY
  6. Jun 15, 202622w ago 8-K Neutral 4/10 Entry $127.87 to $124.26 Now $157.10 +22.86% ▼ −2.82% −0.59% vs SPY
  7. Jun 9, 202622w ago 8-K Neutral 2/10 Entry $132.15 to $127.87 Now $157.10 +18.88% ▼ −3.24% −6.67% vs SPY
  8. Jun 1, 202624w ago 8-K Neutral 4/10 Entry $127.31 to $129.84 Now $157.10 +23.40% ▲ +1.98% +4.73% vs SPY
  9. May 27, 202624w ago 8-K Neutral 4/10 Entry $128.90 to $131.04 Now $157.10 +21.87% ▲ +1.66% +1.34% vs SPY
  10. May 7, 202627w ago 8-K Mixed 6/10 Entry $131.59 to $130.04 Now $157.10 +19.38% ▼ −1.18% −2.69% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026